ANI Pharmaceuticals SVP sells 2,060 common shares

ANI Pharmaceuticals senior vice president Ori Gutwerg reported an open-market sale of company stock.

Rhea-AI Filing Summary

ANI Pharmaceuticals senior vice president Ori Gutwerg reported an open-market sale of company stock. On March 3, 2026, he sold 2,060 shares of Common Stock at a price of $76.50 per share. After this transaction, he directly owned 84,782 common shares.

Insider Trade Summary

Net Seller: 2,060 shares

Net Sell 1 txn

Insider Gutwerg Ori

Role SVP, GENERICS

Sold 2,060 shs ($158K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,060	$76.50	$158K

Holdings After Transaction: Common Stock — 84,782 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider trade did ANI Pharmaceuticals (ANIP) report for Ori Gutwerg?

ANI Pharmaceuticals reported that SVP, Generics Ori Gutwerg executed an open-market sale of 2,060 shares of Common Stock. The transaction occurred on March 3, 2026, at a price of $76.50 per share and was reported as a direct ownership sale.

How many ANI Pharmaceuticals shares did Ori Gutwerg sell and at what price?

Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals Common Stock at $76.50 per share. The transaction was categorized as an open-market or private sale and disclosed as a non-derivative transaction under Form 4 reporting requirements for company insiders.

How many ANI Pharmaceuticals shares does Ori Gutwerg own after this Form 4 sale?

Following the reported sale, Ori Gutwerg directly owned 84,782 shares of ANI Pharmaceuticals Common Stock. This post-transaction balance reflects his remaining direct holdings after selling 2,060 shares in an open-market transaction reported on March 3, 2026.

What was the nature of Ori Gutwerg’s ANI Pharmaceuticals stock transaction?

The transaction was an open-market sale of Common Stock, coded “S” on Form 4. It involved 2,060 non-derivative shares sold at $76.50 per share and was classified as a direct ownership transaction by an executive officer of ANI Pharmaceuticals.

What role does Ori Gutwerg hold at ANI Pharmaceuticals related to this insider filing?

Ori Gutwerg is identified as an officer of ANI Pharmaceuticals with the title “SVP, GENERICS.” As a senior executive, his trades in company Common Stock must be reported on Form 4, including this sale of 2,060 directly owned shares at $76.50 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 06:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gutwerg Ori

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GENERICS

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S		2,060	D	$76.5	84,782	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Ori Gutwerg, by attorney-in-fact Meredith W. Cook	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.